In Q3, Ibsrela saw highest demand since launch and recorded revenue of $78.2 million, marking a growth of 92%. ・Ardelyx’s net ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to DPTX3186, an investigational therapy being ...

Over the past generation, advances in treating common cancers—breast, lung, melanoma, and gastrointestinal (GI)—have improved ...

Purple said that it has achieved a commercially viable yield for IM1240, positioning the program competitively for future ...

Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...

SAN DIEGO, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared ...

Shanghai Zhimeng Biopharma Inc. ( 'Zhimeng') announced that its self-developed new-generation potassium channel opener CB03-154 for the treatment of amyotrophic lateral sclerosis (ALS) has officially ...

Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced clearance by the U.S. Food and Drug Administration (FDA) of ...

BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, ...

The FDA has accepted for review Chiesi’s New Drug Application (NDA) for their investigational maintenance treatment for ...

First orphan designation ever granted to a condensate-modulating therapeuticBuilds on recent IND opening for DPTX3186, a ...